Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsVladimir Coric, MD
Associate Clinical ProfessorDownloadHi-Res Photo
About
Copy Link
Appointments
Education & Training
- Fellowship in Forensic Psychiatry
- Yale University School of Medicine (2001)
- Chief Resident, Post-Traumatic Stress Disorder Firm
- National Center for PTSD, VA Connecticut Healthcare System (2000)
- Program-Wide Chief Resident
- Yale University School of Medicine (2000)
- Yale Psychiatry Residency Training Program
- Yale University School of Medicine (2000)
- MD
- Wake Forest University (1996)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Vladimir Coric's published research.
Publications Timeline
A big-picture view of Vladimir Coric's research output by year.
Angeli Landeros-Weisenberger, MD
Michael Bloch, MD, MS
Dan Oren, MD, BS
John Krystal, MD
Christopher Pittenger, MD, PhD
Evangelos K. Oikonomou, MD, DPhil
95Publications
3,212Citations
Publications
2025
Phase 1 Multiple Ascending Dose Studies Demonstrate Favorable Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator (P9-9.011)
Awsare B, Lerner J, Ashbrenner E, Sevinsky H, Dworetzky S, Jensen C, Killingsworth R, Ivans A, Qureshi I, Coric V, Bozik M. Phase 1 Multiple Ascending Dose Studies Demonstrate Favorable Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator (P9-9.011). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000211227.Peer-Reviewed Original ResearchA Modern Design for a Phase 2/3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BHV-7000 in Idiopathic Generalized Epilepsy with Generalized Tonic-Clonic Seizures (P8-9.016)
Lerner J, Stock D, Bozik M, Suarez V, Jensen C, Donahue L, DeGrosky M, Kozauer N, Coric V, Qureshi I, Kerr W, French J. A Modern Design for a Phase 2/3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BHV-7000 in Idiopathic Generalized Epilepsy with Generalized Tonic-Clonic Seizures (P8-9.016). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000211240.Peer-Reviewed Original ResearchSafety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and Migraine (S11.004)
Granit V, Bertz R, Lucas A, Ashbrenner E, Donohue M, Mydlow P, Jensen C, Vriens J, Voets T, Emerson B, Qureshi I, Coric V. Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and Migraine (S11.004). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000211307.Peer-Reviewed Original ResearchCitationsConceptsBHV-2100, a First-in-Class TRPM3 Antagonist in Development for the Treatment of Migraine (P7-12.009)
Emerson B, Pieters A, Morris B, Lucas A, Granit V, Jensen C, Vriens J, Voets T, Qureshi I, Coric V, Lipton R. BHV-2100, a First-in-Class TRPM3 Antagonist in Development for the Treatment of Migraine (P7-12.009). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000211319.Peer-Reviewed Original ResearchCitations
2024
Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies
Dickson S, Mallinckrodt C, Rogula B, Powell L, Potashman M, Coric V, L’Italien G, Hendrix S. Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies. Neurology And Therapy 2024, 13: 1627-1639. PMID: 39287752, PMCID: PMC11541966, DOI: 10.1007/s40120-024-00661-2.Peer-Reviewed Original ResearchCitationsAltmetricConceptsComposite scaleDisease-modifying therapiesItem-level dataDisease progressionDetect clinically meaningful effectsPlacebo arm dataValidity scalesMeasure disease progressionTreatment effectsClinical declineDMT effectClinically meaningful effectChange scoresAssess treatment effectsDetect disease progressionTreatment outcomesSlow disease progressionMeaningful effectSensitive to disease progressionNeurodegenerative disease progressionItemsResponse outcomesPatient populationStandard itemsNatural history dataTroriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg‐AD mice
Pfitzer J, Pinky P, Perman S, Redmon E, Cmelak L, Suppiramaniam V, Coric V, Qureshi I, Gramlich M, Reed M. Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg‐AD mice. Journal Of Neurochemistry 2024, 169: e16215. PMID: 39214859, DOI: 10.1111/jnc.16215.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTau mouse modelsRestore cognitive deficitsAlzheimer's diseaseSynaptic vesiclesSV pool sizeMouse model of ADCognitive deficitsTau-related pathologyGlutamate releasePool sizeModel of ADHippocampal culturesGlutamate-modulating drugsLoss of glutamatergic synapsesBeta-amyloidGlutamate modulator riluzoleTau pathologyPresynaptic vesicular glutamate transporterVesicular glutamate transportersAD pathologyAccumulation of glutamateMouse modelTau modelStages of ADPresynaptic dysfunctionVideo-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis
L’Italien G, Oikonomou E, Khera R, Potashman M, Beiner M, Maclaine G, Schmahmann J, Perlman S, Coric V. Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis. Neurology And Therapy 2024, 13: 1287-1301. PMID: 38814532, PMCID: PMC11263303, DOI: 10.1007/s40120-024-00625-6.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMovement qualityVideo-based kinematic analysisGait stability measuresTandem walking taskRating of AtaxiaGait qualityGait assessmentGait parametersTandem walkingWalking assessmentsWalking taskSpinocerebellar ataxiaVideo-based assessmentClinical expertiseNatural walkingRandomized participantsGaitHigh riskPost Hoc AnalysisStandardized scalesAdultsWalkingParticipantsHoc AnalysisPhase 3Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson’s Disease Progression Using Parkinson’s Progression Markers Initiative Natural History Data (P11-3.012)
Dickson S, Rogula B, Dubow J, Kozauer N, Powell L, Potashman M, Crimin K, O’Keefe P, Korol E, Crabtree M, Nagase F, Coric V, Hendrix S, L’Italien G. Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson’s Disease Progression Using Parkinson’s Progression Markers Initiative Natural History Data (P11-3.012). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204570.Peer-Reviewed Original ResearchCitationsFunctional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features (P1-1.007)
Berg A, Lerner J, Millichap J, L’Italien G, Coric V, Potashman M. Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features (P1-1.007). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204827.Peer-Reviewed Original ResearchPsychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxia (P7-3.018)
Potashman M, Popoff E, Powell L, Beiner M, Mackenzie A, Coric V, Schmahmann J, L’Italien G. Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxia (P7-3.018). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204549.Peer-Reviewed Original Research
News
Copy Link
Get In Touch
Copy Link